Register for our free email digests:
Latest From Allergan PLC
Failure of stem cell therapy NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.
Anti-obesity device company Apollo Endosurgery is looking to net around $31m through a sale of 5.7 million shares. The Austin, Texas-based company has seen slow sales in the last couple of years and is planning to use the funds to boost adoption of its endo-bariatric products, which includes the Orbera intragastric balloon and the Lap-Band gastric band which it inherited through acquiring Allergan’s obesity intervention division in 2013.
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.
Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- AlzProtect SAS
- Senior Management
- Philippe Verwaerde, PhD, Pres., CEO & CSO
- Contact Info
Phone: (33) 320 29088 61
Batiment Biserte, 1 Place de Verdun
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.